Bio-Rad Labs EPS beats by $0.34, beats on revenue

Bio-Rad Labs (NYSE:BIO): Q1 Non-GAAP EPS of $1.91 beats by $0.34; GAAP EPS of $22.72.

Revenue of $571.6M (+3.2% Y/Y) beats by $25.9M.

Press Release

https://seekingalpha.com/news/3570574-bio-rad-labs-eps-beats-0_34-beats-on-revenue

Qiagen Q1 sales up 7%, increased growth expected this quarter

QIAGEN N.V. (NYSE:QGEN) Q1 results:

Sales: $372.1M (+6.7%).

Molecular diagnostics revenue up 4% to $176M.

Net income: $39.8M (+34.9%); EPS: $0.17 (+30.8%); non-GAAP EPS: $0.34 (+25.9%).

Cash flow ops: $15.9M (-64.4%).

Q2 guidance: Sales growth at least 12%; non-GAAP EPS at least $0.40.

2020 guidance withdrawn.

Qiagen EPS beats by $0.07, beats on revenue

https://seekingalpha.com/news/3570589-qiagen-q1-sales-up-7-increased-growth-expected-this-quarter

Cellular Biomedicine EPS beats by $0.16

Cellular Biomedicine (NASDAQ:CBMG): Q1 GAAP EPS of -$0.60 beats by $0.16.

Cash, equivalents and restricted cash of $21.6M (+40.3% Q/Q)

Press Release

https://seekingalpha.com/news/3570635-cellular-biomedicine-eps-beats-0_16

MyoKardia EPS misses by $0.11

MyoKardia (NASDAQ:MYOK): Q1 GAAP EPS of -$1.50 misses by $0.11.

Cash, cash equivalents and investments of $360.1M.

Press Release

https://seekingalpha.com/news/3570660-myokardia-eps-misses-0_11

Exact Sciences Q1 top line up 115%, cologuard revenue up 36%

Exact Sciences (NASDAQ:EXAS) Q1 results:

Revenue: $347.8M (+114.7%); screening: $219.5M (+35.5%); Precision Oncology: $128.4M.

Net loss: ($105.7M); loss/share: ($0.71).

Non-GAAP EBITDA: ($8.2M) (+81.7%).

Quick assets at quarter-end: $1.2B.

EXACT Sciences EPS misses by $0.04, revenue in-line

https://seekingalpha.com/news/3570483-exact-sciences-q1-top-line-up-115-cologuard-revenue-up-36

Alnylam Pharma Q1 Onpattro sales up 154%; guidance lowered

Alnylam Pharmaceuticals (ALNY) Q1 results:

Revenues: $99.5M (+198.8%); Onpattro sales: $66.7M (+153.6); Givlaari sales: $5.3M; collaborator revenue: $27.5M.

Net loss: ($182.2M) (-0.2%); loss/share: ($1.62) (+6.4%); non-GAAP Net loss: ($171.8M) (-14.6%); non-GAAP loss/share: ($1.52) (-7.0%).

2020 guidance: Onpattro sales: $270M – 300M from $285M – 315M; collaborator revenue: $100M – 150M (unch).

Previously: Alnylam Pharmaceuticals EPS misses by $0.01, beats on revenue (May 6)

https://seekingalpha.com/news/3570092-alnylam-pharma-q1-onpattro-sales-up-154-guidance-lowered

Sinovac COVID-19 vaccine shows positive effect in preclinical study

Sinovac Biotech Ltd. (SVA) announces encouraging results from a preclinical animal study for its inactivated SARS-CoV-2 vaccine candidate.

The challenge study in mice, rats and rhesus macaques showed that it was safe and provided complete protection against SARS-CoV-2 strains (in the primates) according to Chairman Weidong Yin.

A Phase 1 study in healthy human volunteers is underway.

Trading in the U.S. has been suspended since February 22, 2019, pending the submission of additional information requested by Nasdaq.

https://seekingalpha.com/news/3570106-sinovac-covidminus-19-vaccine-shows-positive-effect-in-preclinical-study